The Quiet Consolidation of Cancer Care
Oncology has long been one of the most specialized and emotionally weighted corners of medicine – patients arriving at a cancer diagnosis expect continuity, trust, and a care team that knows their history. What many of those patients don’t know is that the practice their oncologist built over two decades may now be owned by a private equity firm operating out of a midtown Manhattan office. The transaction happened quietly, announced in a brief press release or not at all, and the staff kept showing up Monday morning as if nothing had changed.
Across the country, regional oncology practices – the kind that serve mid-sized cities and suburban corridors where a major academic medical center is too far to drive – are selling to private equity-backed rollup platforms at a pace that has caught even some oncologists off guard. The deals are structured carefully, the branding often stays intact, and the physicians sometimes remain on as employees with equity stakes in the larger platform. But the ownership structure, the financial incentives, and the long-term direction of care are no longer in the hands of the doctors delivering it.
Why Oncology, and Why Now
Cancer care generates revenue across a long, complex treatment cycle. A single patient may require surgery, chemotherapy, radiation, immunotherapy, imaging, genetic testing, and ongoing monitoring – each of those touchpoints generating a billable event. Oncology practices that have built out in-house infusion centers and diagnostic capabilities are especially attractive, because they’ve already consolidated the revenue streams that PE platforms would otherwise need to build or acquire separately. The practice isn’t just a physician’s schedule – it’s a mini-healthcare system already operating under one roof.
The financial mechanics behind these acquisitions follow a familiar pattern seen in regional cardiology practice consolidation: buy multiple independent practices, standardize billing and operations, reduce redundant administrative overhead, and negotiate from a position of scale with insurers and drug manufacturers. In oncology, the drug margin piece is particularly significant. Oncology practices often buy specialty drugs at one price and bill insurance at a higher rate, a spread called “buy and bill” that can account for a substantial portion of a practice’s operating income. A platform with 20 locations purchasing those drugs in bulk has an advantage that a two-physician practice in Tulsa simply cannot replicate.
Physician burnout and succession planning are doing as much work as any financial model. A 58-year-old oncologist who built a practice from scratch, carried the administrative weight for three decades, and watched reimbursement rates compress year after year is not necessarily motivated by ideology when a PE offer arrives. The offer provides liquidity, removes operational stress, and often includes a multi-year employment contract. For physicians without a natural successor – and oncology faces real shortages in the pipeline – the alternative may be a forced retirement or a sale to a hospital system that comes with even less autonomy.
What Changes After the Sale
The most immediate changes tend to be administrative rather than clinical. Scheduling systems get unified, billing moves to a centralized platform, and staffing decisions that once belonged to the founding physician now require approval from a regional operations director. Those shifts can feel bureaucratic and distant, but they’re not inherently harmful to patient care.
The harder questions surface over a longer time horizon. PE funds typically operate on a five-to-seven year exit cycle, which means the platform built today is designed to be sold again – to a larger platform, a hospital system, or a publicly traded company. Each transaction adds a new layer of financial obligation to the enterprise, and those obligations eventually have to be serviced from somewhere. In a care setting where treatment decisions carry life-or-death weight, the pressure to hit EBITDA targets is not a neutral background condition.
The Patient Experience Gap
Patients rarely know when a practice changes ownership. There’s no legal requirement to notify them, and the staff continuity maintained during a transition actively works against any sense that something has changed. A patient who has been seeing the same oncologist for four years continues to see that same oncologist – at least initially. The friction tends to appear later: longer wait times as the practice expands volume to justify the acquisition price, staff turnover driven by compensation restructuring, or formulary decisions that favor drugs with better margin profiles.
That last point deserves attention. An independent oncologist chooses a treatment protocol based on clinical evidence, patient history, and professional judgment. A PE-backed platform with a preferred drug purchasing agreement has a structural incentive – not necessarily a mandate, but an incentive – for the portfolio to trend toward certain products. Whether that incentive meaningfully influences prescribing behavior at the individual physician level is genuinely difficult to measure, and most platforms would push back hard on the suggestion. But the conflict exists in the structure regardless of whether anyone acts on it.
Staffing is where the pressure becomes most visible. Oncology nurses and patient navigators are the connective tissue of cancer care – they manage treatment schedules, handle the calls from frightened patients at 10 p.m., and catch errors before they become crises. Those roles are also among the first targeted for efficiency when a platform needs to improve its margin profile ahead of a refinancing or an exit. Practices that once ran lean by choice now run lean by financial requirement, and the difference matters in a specialty where emotional continuity is part of the treatment.
Rural and semi-rural communities face the sharpest version of this tension. Many of the practices being acquired are the only oncology option within a reasonable driving distance for their patient populations. When the economics of a rollup require closing an underperforming satellite location, the patients who relied on that office don’t gain access to a better-resourced urban center – they lose access entirely, or they face a commute that makes consistent treatment genuinely difficult. A patient missing infusion appointments because of transportation isn’t a billing problem. It’s a survival problem.
Regulators have been slow to catch up. Most oncology PE transactions fall below the thresholds that trigger mandatory antitrust review, and the patchwork of state-level corporate practice of medicine rules – which are supposed to prevent non-physicians from controlling clinical decisions – has proven difficult to enforce against holding company structures that are designed specifically to stay on the right side of those rules on paper. The Federal Trade Commission has signaled increased attention to healthcare consolidation broadly, but oncology rollups remain a relatively quiet corner of a loud debate about who owns American medicine.
